Diagnostics News and Research

RSS

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial of Lymphoseek (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma received the 1st Investigator Award at the 2nd InternationaI Symposium on Thoracic and Upper Aerodigestive Malignancies.

15 Apr 2013

Matrix-Bio, Quest Diagnostics enter global licensing agreement for metabolomic biomarkers

Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics, the world's leading provider of diagnostic information services. Under the agreement, Quest Diagnostics will have the rights to use the biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence.

From Quest Diagnostics 12 Apr 2013

New initiative launched to create more effective ED therapies based on brain imaging studies

Current treatments for anorexia and bulimia nervosa, which afflict an estimated 10 to 24 million Americans, are often limited and ineffective.

12 Apr 2013

Abbott's ARCHITECT Galectin-3 assay earns CE mark

Abbott today announced CE Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure.

11 Apr 2013

FDA lengthens review periods for IVD tests that utilize molecular biomarkers

FDA review periods are lengthening for IVD tests that utilize molecular biomarkers, and at a faster rate than for IVDs overall, one of the key findings in a new report published this month by Amplion Research.

11 Apr 2013

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Precision Biologics announced today that in conjunction with researchers from Precsion Biologics , Johns Hopkins Medical Center and Duke University Medical Center presented updated clinical data from the phase I study of Ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers

11 Apr 2013

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

10 Apr 2013

Research: African-Americans with ABCA7 gene variant have double risk of developing AD

African-Americans with a variant of the ABCA7 gene have almost double the risk of developing late-onset Alzheimer's disease compared with African-Americans who lack the variant.

10 Apr 2013

Five Japanese drug makers form PPP to accelerate development of drugs, vaccines for infectious diseases

"Five Japanese pharmaceutical giants are teaming up with the Bill & Melinda Gates Foundation and Japan's government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries," GENNews reports (4/8).

10 Apr 2013

Researchers use metagenomics to reconstruct genome sequence of Shiga-toxigenic Escherichia coli

Researchers have been able to reconstruct the genome sequence of an outbreak strain of Shiga-toxigenic Escherichia coli using metagenomics (the direct sequencing of DNA extracted from microbiologically complex samples), according to a study in the April 10 issue of JAMA, a Genomics theme issue.

10 Apr 2013

REVEAL trial: VASCAZEN meets primary endpoint

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.

10 Apr 2013

OTraces completes Phase II testing for blood test that detects breast cancer

OTraces, Inc., a Maryland-based biotech company developing blood tests for cancer diagnosis, announces completion of Phase II testing for a blood test that screens women for breast cancer.

10 Apr 2013

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

10 Apr 2013

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.

9 Apr 2013

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.

9 Apr 2013

Rheumatoid arthritis blood tests launched by Quest Diagnostics

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the availability of two new blood tests for aiding the early diagnosis of arthritis (RA), an autoimmune disorder that can cause debilitating joint damage.

From Quest Diagnostics 9 Apr 2013

New national study examines marijuana use and prescription drug misuse

Individuals who use marijuana recreationally are more likely to misuse other drugs, including pain-controlling, but potentially addictive narcotics, sedatives and other prescription medications, than individuals who do not use marijuana, according to a new national study issued today by Quest Diagnostics, the world's leading provider of diagnostic information services.

From Quest Diagnostics 9 Apr 2013

Diagnostics News and Research

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Matrix-Bio, Quest Diagnostics enter global licensing agreement for metabolomic biomarkers

New initiative launched to create more effective ED therapies based on brain imaging studies

Abbott's ARCHITECT Galectin-3 assay earns CE mark

FDA lengthens review periods for IVD tests that utilize molecular biomarkers

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

Research: African-Americans with ABCA7 gene variant have double risk of developing AD

Five Japanese drug makers form PPP to accelerate development of drugs, vaccines for infectious diseases

Researchers use metagenomics to reconstruct genome sequence of Shiga-toxigenic Escherichia coli

REVEAL trial: VASCAZEN meets primary endpoint

OTraces completes Phase II testing for blood test that detects breast cancer

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Rheumatoid arthritis blood tests launched by Quest Diagnostics

New national study examines marijuana use and prescription drug misuse

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Researchers identify four genes newly associated with severe childhood obesity

GE Healthcare releases next-generation sequencing assay for use in clinical trials

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News